Cure My Disease

Don't miss your cure!

 Log in / Sign up

Left vs. right brain stimulation: which side affects thinking more?

NCT ID NCT07777419

Knowledge-focused Sponsor: Insel Gruppe AG, University Hospital Bern Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Sep 04, 2026 · Updated 2 times

Summary

This study investigates how deep brain stimulation (DBS) affects cognitive and psychiatric symptoms in people with Parkinson's disease. Researchers will compare the effects of stimulating the left versus the right hemisphere of the brain on tasks like verbal fluency and impulsivity. Participants will have DBS temporarily turned off on one side at a time during the experiment. The goal is to understand if side-specific stimulation leads to different thinking or mood changes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Deep brain stimulation (DBS) of the subthalamic nucleus, tested with one hemisphere turned off at a time
What this could lead to
If it works, this could help doctors tailor DBS settings to minimize thinking and mood side effects in Parkinson's patients.
What could go wrong
This is a small, early-stage study with only 20 participants, so results may not apply to everyone. Turning off DBS temporarily could cause temporary worsening of symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed with Parkinson's disease * Treated with subthalamic nucleus deep brain stimulation (STN-DBS) * For part I: General research consent for the analysis of routine clinical data * For part II of the study: ability to provide informed consent * native German or French speaker * Montreal Cognitive Assessment with score ≥ 20 Exclusion Criteria: * Atypical Parkinsonism * Other disease affecting the brain (e.g. Alzheimer's disease, vascular dementia, multiple sclerosis, stroke, traumatic brain injury, non-provoked epilepsy, brain tumour, etc.) * Haemorrhage during implantation of STN-DBS, which resulted in permanent cognitive or physical impairment * Schizophrenia, ongoing substance abuse, bipolar disorder or autism * For part II: Severe depressive disorder and/or suicidality * Insufficient quality or lack of brain imaging data pre and/or post STN-DBS

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinsons disease (PD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinsons disease (PD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital Inselspital, Berne

    RECRUITING

    Bern, 3010, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.